FLAGSTAR FINANCIAL, INC. TO REPORT FIRST QUARTER 2025 EARNINGS AND HOST CONFERENCE CALL ON APRIL 25TH
HICKSVILLE, N.Y., April 2, 2025 /PRNewswire/ -- Flagstar Financial, Inc. (NYSE: FLG) (the 'Company') today announced that it plans to issue results for the three months ended March 31, 2025 at approximately 6:00 a.m. Eastern Time (ET) on Friday, April 25, 2025. The earnings release and presentation will be posted to the Investor Relations portion of the Company's website, ir.flagstar.com shortly after issuance.
The Company will conduct a conference call at 8:00 a.m. (ET) on the same date, during which Chairman, President, and Chief Executive Officer, Joseph M. Otting and Senior Executive Vice President and Chief Financial Officer, Lee Smith will discuss the Company's first quarter 2025 performance.
Conference Call Dial-In Instructions:
Once you dial-in to the call, please enter the conference ID (5857240) and press #. You will then be prompted to provide your name and company name before being placed directly into the call. Participants should dial-in at least 15 minutes in advance of the call start time.
The conference call will be simultaneously webcast at ir.flagstar.com and archived through 5:00 p.m. on May 23, 2025.
Conference Call Details:
About Flagstar Financial, Inc.
Flagstar Financial, Inc. is the parent company of Flagstar Bank, N.A., one of the largest regional banks in the country. The Company is headquartered in Hicksville, New York. At December 31, 2024, the Company had $100.2 billion of assets, $69.2 billion of loans, deposits of $75.9 billion, and total stockholders' equity of $8.2 billion.
Flagstar Bank, N.A. operates over 400 locations across 10 states, including a significant presence in the Northeast and Midwest and locations in high growth markets in the Southeast and West Coast. In addition, the Bank has approximately 80 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high-net worth individuals and their businesses.
Investor Contact:
Media Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
Yahoo
2 hours ago
- Yahoo
What To Expect From Lennar's (LEN) Q2 Earnings
Homebuilder Lennar (NYSE:LEN) will be announcing earnings results tomorrow after market close. Here's what investors should know. Lennar beat analysts' revenue expectations by 2% last quarter, reporting revenues of $7.63 billion, up 4.4% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' backlog estimates. Is Lennar a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lennar's revenue to decline 5.5% year on year to $8.29 billion, a reversal from the 9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.94 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lennar has missed Wall Street's revenue estimates twice over the last two years. With Lennar being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for industrials stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Lennar is down 2.3% during the same time and is heading into earnings with an average analyst price target of $132.69 (compared to the current share price of $108.64). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Business Wire
13 hours ago
- Business Wire
Perma-Pipe International Holdings, Inc.公布2025會計年度第一季財務業績
德州斯普林--(BUSINESS WIRE)--(美國商業資訊)-- Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH)今天公布了截至2025年4月30日的第一季財務業績。 總裁兼執行長Saleh Sagr指出：「第一季銷售額為4670萬美元，較去年同期的3430萬美元成長1240萬美元，增幅36.2%。歸屬於普通股的淨收入為500萬美元，較上年第一季的140萬美元成長360萬美元，增幅達243%。」 Sagr先生繼續說道：「目前未完成訂單為1.311億美元，相較2025年1月31日的1.381億美元減少700萬美元。然而，相較2024年4月30日的6310萬美元，該公司的未完成訂單大幅增加6800萬美元，增幅達108%。我們對現有未完成訂單水準感到鼓舞，其仍為去年第一季末報告之未完成訂單水準的兩倍以上。」 總裁兼執行長Saleh Sagr表示：「第一季業績代表公司實現了前所未見的業務表現，無論是銷售額還是歸屬於普通股的淨收入，均為2017年從MFRI轉變為Perma-Pipe以來第一季的最高水準。此外，第一季歸屬於普通股的淨收入約占公司2024會計年度全年業績的55%。」 Sagr先生評論道：「我們對各市場的業務活動水準感到滿意，這推動了第一財季整體銷售額和收益的成長。此外，美洲和中東及北非(MENA)地區的業績表現令人振奮，兩個地區在第一季取得了不相上下的業績。」 Sagr先生總結道：「公司第一季業績的強勁表現為2025會計年度剩餘季度提供了顯著的發展動力。我們認為公司已做好充分準備，將繼續利用這一動力，進一步參與MENA地區的發展計畫，並在北美地區取得更多市場佔有率。」 2025會計年度第一季業績 截至2025年4月30日的三個月和2024年4月30日的三個月，淨銷售額分別為4670萬美元和3430萬美元。增加的1240萬美元（增幅36%）主要是由於中東和北美的銷售量增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，毛利分別為1670萬美元（占淨銷售額的36%）和1050萬美元（占淨銷售額的31%）。增加的620萬美元主要是由於業務量增加以及產品組合帶來的更高利潤率。 截至2025年4月30日的三個月和2024年4月30日的三個月，一般和行政支出分別為770萬美元和610萬美元。增加的160萬美元是由於本季度薪資支出和專業服務費的增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，銷售支出保持穩定，分別為110萬美元和120萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，淨利息支出保持穩定，分別為40萬美元和50萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，其他支出保持穩定，均低於10萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，公司的有效稅率(ETR)分別為21%和30%。ETR的變動是由於各司法管轄區的盈虧構成不同。 截至2025年4月30日的三個月和2024年4月30日的三個月，歸屬於普通股的淨收入分別為500萬美元和140萬美元。增加的360萬美元主要是由於本季度銷售量增加以及更好的專案執行。 關於Perma-Pipe International Holdings, Inc. Perma-Pipe International Holdings, Inc.（簡稱「公司」）是針對石油和天然氣採集、區域供熱和製冷以及其他應用的預絕緣管道和洩漏偵測系統的全球領導者。公司利用其廣泛的工程和製造專長開發管道解決方案，以解決多種液體安全高效運輸的複雜挑戰。公司總計在六個國家的14個據點經營業務。 前瞻性陳述 本新聞稿中包含的某些陳述和其他資訊可以透過使用前瞻性術語來辨識，構成《1933年證券法》（修訂版）第27A條和《1934年證券交易法》（修訂版）第21E條所定義的「前瞻性陳述」，並受到其中包含的安全港條款的約束，包括但不限於有關公司未來預期業績和營運的陳述。這些陳述應被視為受到公司營運和業務環境中存在的許多風險和不確定性的影響。這些風險和不確定因素包括但不限於以下內容：(i)石油和天然氣價格的波動及其對公司產品客戶訂單量的影響；(ii)公司以優惠價格購買原物料並與供應商保持良好關係的能力；(iii)使用公司產品的政府專案支出減少，以及公司的非政府客戶在流動性和獲得資本資金方面面臨挑戰；(iv)公司償還債務和續延即將到期的國際信貸便利的能力；(v)公司有效執行策略計畫以及實現持續盈利和正現金流的能力；(vi)公司收取與中東專案有關的長期應收帳款的能力；(vii)公司解讀稅收法規和立法變化的能力；(viii)公司利用其淨經營虧損結轉的能力；(ix)由於公司在「超時」確認收入時估計不準確，導致以前記錄的收入和利潤逆轉；(x)公司未能建立和維護有效的財務報告內部控制；(xi)公司產品的訂單接收、執行、交付和驗收時間；(xii)公司就大額合約的進度帳單安排進行成功談判的能力；(xiii)現有競爭對手的激進定價以及新競爭對手進入公司經營的市場；(xiv)公司製造無潛在缺失產品的能力，以及向可能為公司提供有缺失材料的供應商追償的能力；(xv)公司未完成訂單中訂單的減少或取消；(xvi)公司國際業務營運特有的風險和不確定性；(xvii)公司吸引和留住高階管理人員和關鍵員工的能力；(xviii)公司實現成長計畫預期效益的能力；(xix)流行病和其他公共衛生危機對公司及其營運的影響；以及(xx)網路安全威脅對公司資訊技術系統的影響。請股東、潛在投資人和其他讀者在評估前瞻性陳述時仔細考量這些因素，並注意不要過分依賴此類前瞻性陳述。此處所做的前瞻性陳述僅反映本新聞稿發表之日的情況。無論是由於新資訊、未來事件還是其他原因，我們概不承擔公開更新任何前瞻性陳述的義務。有關可能影響我們業績的因素的更多詳細資訊，請參閱我們向美國證券交易委員會遞交的文件，這些文件可在 以及我們網站的「投資人中心」(Investor Center)部分( 公司財政年度截止日為每年1月31日。本報告所述2025年、2024年及2023年財務資料，分別對應截至2026年1月31日、2025年1月31日及2024年1月31日止的財務年度。 有關公司截至2025年1月31日財政年度財務業績的更多資訊，包括管理層對公司財務狀況和經營成果的討論與分析，載於公司截至2025年1月31日的10-Q表年報，這些資料將於本報告發表之日或前後遞交給美國證券交易委員會，並可透過 和 查閱。如欲瞭解更多資訊，請造訪公司網站。 PERMA-PIPE INTERNATIONAL HOLDINGS, INC.及子公司 簡明合併資產負債表 （以千為單位） （未經稽核） 2025年4月30日 2025年1月31日 資產 流動資產 $ 120,700 $ 108,802 長期資產 57,615 56,439 資產總額 $ 178,315 $ 165,241 負債與股東權益 流動負債 $ 61,751 $ 54,063 長期負債 26,459 28,073 負債總額 88,210 82,136 非控制權益 12,238 10,967 股東權益 77,867 72,138 負債和權益總額 $ 178,315 $ 165,241 Expand 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
